Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.

Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, preventing complement fixation and cytotoxicity mediated by antibody; CZP does not actively cross the placenta, unlike other TNFi. RAPID-axSpA study is a Phase III trial conducted in patients with AS and nr-axSpA as double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Of a total of 325 patients recruited, 107 patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W, 107 to CZP 400 mg Q4W). Improvements in axial involvement, joint involvement, enthesitis and quality of life were reported in patients treated with CZP. Safety profile was like that reported for other TNFi in axSpA patients. In this article, we summarized the pharmacology and we reviewed the efficacy and tolerability of this drug for the treatment of axSpA. Some special considerations of CZP during pregnancy are included. CZP, the latest TNFi to be approved, showed efficacy in all manifestations of AS and nr-axSpA.

RCT Entities:   Population Interventions Outcomes

Introduction

Axial spondyloarthritis (axSpA) is a chronic disease, characterized by involvement of the sacroiliac (SI) joints and spine, resulting in chronic inflammatory back pain.

The estimated prevalence of axSpA is between 0.2% and 1.2% in white European populations.1 The diagnosis is often delayed by up to 8 years, mainly because sacroiliitis, which is considered a hallmark of ankylosing spondylitis (AS), is not visible on plain radiographs in the early stages of the disease.2,3

For the diagnosis of AS, fulfillment of modified New York classification criteria, which requires the presence of radiographic sacroiliitis, is needed.4 With the use of magnetic resonance imaging (MRI) allowing earlier detection of inflammation in the SI joints, it has been possible to identify patients with clinical characteristics of AS, but who do not fulfill the modified New York criteria. These patients have been classified as having non-radiographic axSpA (nr-axSpA).5,6 New classification criteria4–7 were developed in an attempt to improve diagnostic delay.8,9 This new criteria allowed the inclusion of nr-axSpA in clinical studies.

It has been proposed that nr-axSpA may represent an early form of AS, as many patients progress to AS over time.10,11 The fact that not all patients progress to AS over time, and the identification of genetic and sex differences between AS and nr-axSpA, has led some to think that they might be distinct diseases12–14 and have led to the reluctance of FDA to approve tumor necrosis factor inhibitors (TNFis) in nr-axSpA.15 In general, disease activity and burden of symptoms did not differ between both, and both need the same kind of treatment.16–19

The treatment of SpA has changed drastically since the use of biological agents such as TNFi.20–23 Certolizumab pegol (CZP), a novel TNFi, was the last TNFi approved for the treatment of axSpA (European Commission [EMA] and AS (EMA and FDA). We will describe the current evidence for the use of CZP in the treatment of active axSpA in the following text.

Certolizumab pegol

CZP is formed by the combination of a humanized Fab fragment (50 kDa) and a 40-kDa polyethylene glycol moiety (a polymer that is not immunogenic or toxic).24,25 Its molecular structure leads to an increase of plasma half-life of the molecule to about 2 weeks. This allows 2–4 weekly subcutaneous injections. PEGylation is also assumed to be associated with decreased inmmunogenicity.25 The lack of Fc region prevents complement fixation and cytotoxicity mediated by antibody. CZP does not lead to apoptosis of peripheral blood monocytes or lymphocytes or neutrophil necrosis.24,25

CZP has been characterized as producing dose-dependent inhibition of TNF (soluble and membrane-bounded TNF) and inhibition of the production of lipopolysaccharide-induced TNF-α and IL-1β by monocytes. CZP does not induce complement or cytotoxicity mediated by antibody in vitro and induces cell death by a nonapoptotic signaling (probable by transmembrane TNF-α). It has also been shown greater drug distribution into inflamed tissues than that of infliximab (IFX) and adalimumab (ADA).24,26

Clinical efficacy

CZP efficacy in the treatment of both AS and nr-axSpA patients was evaluated by a randomized control trial: RAPID-axSpA trial.27–32

The objective of RAPID-axSpA (NCT01087762), a 4-year, Phase III randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204, was to study the efficacy and safety of CZP for the treatment of axSpA.27–32

Patients were recruited from 83 different sites in central/Eastern and Western Europe, North America and Latin America. To be included in the study, patients need to fulfill Assessment of SpondyloArthritis international Society (ASAS) criteria for the diagnosis of SpA and to have active disease, defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 and spinal pain ≥4 on a 0–10 Numerical Rating Scale. Intolerance or inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID) was also needed.28 A total of 325 patients were recruited. One hundred and seven patients were assigned to placebo and 218 patients to CZP (111 to CZP 200 mg Q2W and 107 to CZP 400 mg Q4W). Of the group of patients treated with CZP, 121 had AS and 97 had nr-axSpA (Figure 1).28 Baseline disease activity among the groups of patients and between AS and nr-axSpA patients was similar. More than half of the patients in the CZP-treated group (63% [199/315]) completed the study at week 204. The completion rates were similar between both CZP groups and between AS and nr-axSpA patients. ASAS20, ASAS40, BASDAI, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Metrology Index and Bath Ankylosing Spondylitis Functional Index responses (nonresponder imputation and observed case) at week 204 are shown in Table 1.31,32

Figure 1

Chart flow of RAPID-axSpA trial27–32 during the three different phases of the trial.

Abbreviations: CZP, certolizumab pegol; axSpA, axial spondyloarthritis.

Table 1

Efficacy of subcutaneous certolizumab pegol in adult patients with axial spondyloarthritis in the randomized, double-blind, multicenter RAPID-axSpA trial28

Outcome	All patients axSpA (N= 218)					AS (N = 121)					nr-axSpA (N = 97)
	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204
	N = 218	OC (N = 205)	Imputed	OC (N = 140)	Imputed	N = 121	OC (N = 112)	Imputed	OC (N = 80)	Imputed	N= 97	OC (N = 93)	Imputed	OC (N =60)	Imputed
ASDAS-ID, n/N (%)		66/205(32.2)	66(30.3)	44/140(31.4)	70(32.1)		33/112(29.5)	33(27.3)	23/80(28.8)	39(32.2)		33/93(35.5)	33(34)	21/60(35)	31(32)
ASDAS-MD, n/N (%)	3 (1.4)	51/205(24.9)	54(24.8)	41/140(29.3)	59(27.1)	2 (1.7)	27/112(24/1)	29(24)	25/80(31.3)	33(27.3)	1 (1)	24/93(25.8)	25(25.8)	16/60(26.7)	26(26.8)
ASAS20, n/N (%)		147/201(73.1)	149(68.3)	113/135(83.7)	118(54.1)		81/108(75)	83(68.6)	64/75(85.3)	68(56.2)		66/93(71)	66(68)	49/60(81.7)	50(51.5)
ASAS40, n/N (%)		111/201(55.2)	113(51.8)	91/135(68.1)	96(44)		62/108(57.4)	64(52.9)	51/75(68)	54(44.6)		49/93(52.7)	49(50.5)	41/60(68.3)	42(43.3)
ASAS 5/6, n/N (%)		90/199(45.2)	92(42.2)	72/134(53.7)	75(34.4)		48/108(44.4)	48(39.7)	40/75(53.3)	41(33.9)		42/91(46.2)	44(45.4)	32/59(54.2)	34(35.1)
ASAS-PR, n/N (%)		66/204(32.4)	66(30.3)	50/137(36.5)	51(23.4)		34/111(30.6)	34(28.1)	25/77(32.5)	26(21.5)		32/93(34.4)	32(33)	25/60(41.7)	25(25.8)
BASDAI ≤2 PCR normal, n/N (%)		66/205(32.2)	66(30.3)	46/142(32.4)	72(33)		33/112(29.5)	33 (27.3)	23/81(28.4)	38(31.4)		33/93(35.5)	33(34)	23/61(37.7)	34(35.1)
BASDAI 50, n/N (%)		114/205(55.6)	114(52.3)	89/140(63.6)	89(40.8)		59/112(52.7)	59(48.8)	51/80(63.8)	51(42.1)		55/93(59.1)	55(56.7)	38/60(63.3)	38(39.2)
Mean (SD) ASDAS	3.8(0.9)	2(1)	2.1(1.1)	1.9(0.9)	2(1.1)	3.9(0.99)	2(1)	2(1.1)	2(0.9)	2.1(1.2)	3.8(0.8)	2(1.1)	2(1.1)	1.8(1)	1.9(1)
Mean (SD) BASDAI	6.4(1.5)	3.2(2.2)	3.3(2.3)	2.7(2)	3(2.3)	6.4(1.5)	3.2(2.1)	3.4(2.2)	2.8(1.9)	3(2.3)	6.6(1.5)	3.2(2.5)	3.3(2.5)	2.6(2.2)	2.9(2.3)
Mean (SD) BASFI	5.3(2.3)	2.9(2.5)	3(2.5)	2.6(2.2)	2.7(2)	5.6(2.3)	3.2(2.6)	3.3(2.6)	2.9(2.2)	3(2.4)	5(2.3)	2.6(1.5)	2.6(1.5)	2.4(1.2)	2.5(1.3)
Mean (SD) BASMI-linear	3.8(1.7)	3.2(1.7)	3.2(1.7)	3.1(1.7)	3.1(1.7)	4.2(1.7)	3.6(1.7)	3.6(1.7)	3.6(1.8)	3.6(1.8)	3.2(1.5)	2.6(1.5)	2.6(1.5)	2.4(1.2)	2.5(1.3)

Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; n/N, number positive/number included; ASAS, Assessment of SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS-PR, Assessment of SpondyloArthritis international Society Partial Remission criteria; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index.

Ankylosing Spondylitis Disease Activity Score-ID sustained remission, and ASAS partial remission was achieved by one-third of patients with similar responses rates among AS and nr-axSpA (Table 1).27,32

Patient-reported outcomes

Patients-reported outcomes (PROs) are widely used measurements that allow the collection of information related to specific disease aspects, usually not scored by the physicians, directly from the patient. Among them, improvements in back pain, fatigue, sleep (Medical Outcomes Study Sleep Scale), SF-36 (both physical and mental outcomes) and Ankylosing Spondylitis Quality of Live were seen after 24 weeks of the initiation of treatment with CZP, and these results were maintained until week 20428,31 (Table 2). Comparable improvement in total back pain, fatigue and Ankylosing Spondylitis Quality of Live was seen in AS and nr-axSpA groups.28 Clinically relevant improvement in pain response to CZP was observed as rapid as from day 2.30

Table 2

Effect of subcutaneous certolizumab pegol on key patient-reported outcomes in the RAPID-axSpA study30

Patient-reported outcome	All patients (N = 218)					AS (N = 121)					nr-axSpA (N = 97)
	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204
	N = 218	OC (N = 205)	Imputed	OC (N = 140)	Imputed	N =121	OC (N = 112)	Imputed	OC (N = 80)	Imputed	N = 97	OC (N = 93)	Imputed	OC (N = 60)	Imputed
Morning stiffness	6.6(1.9)	2.9(2.4)	3(2.5)	2.5(2)	2.7(2.4)	6.6(1.9)	2.9(2.1)	3.1(2.2)	2.5(1.9)	2.7(2.3)	6.6(1.9)	3(2.8)	3(2.8)	2.5(2.2)	2.6(2.5)
Fatigue	6.8(1.8)	3.9(2.6)	4.1(2.7)	3.2(2.2)	3.6(2.6)	6.7(1.9)	3.9(2.5)	4.1(2.6)	3.3(2.2)	3.6(2.6)	6.9(1.8)	3.9(2.7)	4(2.7)	3.1(2.3)	3.6(2.6)
Sleep	49(19.2)	35.3(20.1)	36.2(20.2)	32.4(17.3)	34.4(18.6)	46.8(19.9)	35.1(19.3)	36.3(19.5)	32.3(15.9)	34.1(17.5)	51.7(18)	35.4(21.2)	36.1(21)	32.5(19.2)	34.9(20)
Nocturnal back pain	6.9(2.3)	3.1(2.6)	3.3(2.7)	2.7(2.4)	3(2.7)	6.8(2.3)	3.1(2.4)	3.3(2.6)	2.7(2.3)	3.1(2.6)	7(2.3)	3.1(2.9)	3.2(2.9)	2.7(2.6)	2.9(2.7)
Total back pain	7(1.9)	3.5(2.6)	3.8(2.7)	3(2.4)	3.3(2.7)	7(2)	3.5(2.3)	3.8(2.5)	3.1(2.3)	3.4(2.7)	7(1.8)	3.6(2.9)	3.8(3)	2.8(2.5)	3.3(2.7)
ASQoL	11.6(4.4)	6.2(5.5)	6.5(5.6)	4.9(5)	5.7(5.4)	11.6(4.4)	6.3(5.3)	6.8(5.6)	5.2(4.9)	5.9(5.5)	11.6(4.4)	6.1(5.7)	6.1(5.7)	4.5(5.1)	5.3(5.3)
SF-36 PCS	32.4(7.5)	42.1(10)	41.8(9.9)	44.3(9.4)	43.5(9.6)	31.7(7.2)	41.3(9.6)	40.7(9.6)	43.7(9.5)	42.8(10)	33.2(7.9)	43.2(10.4)	43.1(10.3)	45.1(9.2)	44.4(9)
SF-36 MCS	41(12)	46.6(11.6)	46(11.8)	46.8(11)	45.6(11.5)	41.7(11.5)	46.8(11.1)	45.8(11.6)	45.8(10.7)	44.8(11.3)	40.1(12.6)	46.5(12.2)	46.2(12.1)	48.1(11.4)	46.6(11.6)

Note: Values are given as mean and (SD), unless stated otherwise.

Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; SF-36 PCS, Short Form (36) Health Survey Physical Component Summary; SF-36 MCS, Short Form (36) Health Survey Mental Component Summary.

Peripheral arthritis and enthesitis

By week 24, similar improvements in arthritis and enthesitis were seen in both AS and nr-axSpA patients,28 which was maintained until week 204 (Table 3).27 Enthesitis was assessed by the MASES score. Both AS and nr-axSpA patients had a similar improvement in mean MASES score, although baseline scores were higher in nr-axSpA patients (AS: 4.7 and nr-axSpA: 5.6).28

Table 3

Effect of subcutaneous certolizumab pegol on peripheral arthritis and enthesitis in the RAPID-axSpA study28

Articular manifestations, mean (SD)	All patients axSpA (N = 218)					AS (N = 121)					nr-axSpA (N = 97)
	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204	Baseline	Week 24	Week 24	Week 204	Week 204
		OC	LOCF	OC	LOCF		OC	LOCF	OC	LOCF		OC	LOCF	OC	LOCF
Swollen joint count	N = 76Mean 4.2SD 5.6	N = 72Mean 1.2SD 2.7	N = 1.5Mean 3.2	N = 52Mean 0.4SD 1.1	N = 0.8Mean 2.4	N = 42Mean 4SD 4.6	N = 38Mean 1.2SD 1.9	N = 1.7Mean 3.1	N = 28Mean 0.1SD 0.4	N = 1Mean 3	N = 34	N = 34Mean 4.5SD 6.8	N = 1.2Mean 3.4	N = 24Mean 0.7SD 1.5	Mean 2.6SD 2.5
Tender joint count	N = 138Mean 6.3SD 7.1	N = 131Mean 3.3SD 6.4	N = 3.6SD 6.5	N = 89Mena 2.4SD 5	N = 2.9SD 5.5	N = 74Mean 5.9SD 6.5	N = 69Mean 2.7SD 4.7	N = 3SD 4.8	N = 48Mean 2.1SD 5	N = 3SD 5.7	N = 64Mean 6.8SD 7.7	N = 62Mean 4.1SD 7.8	N = 4.3SD 8	N = 41Mean 2.7SD 5.1	N = 2.8SD 5.3
Enthesitis MASES	N = 148Mean 5.1SD 3.5	N = 141Mean 2.2	N = 2.3SD 3.5	N = 104Mean 1.4SD 2.5	N = 1.7SD 3	N = 78Mean 4.7SD 3.4	N = 74Mean 1.6SD 2.7	N =1.7SD 2.7	N = 58Mean 1.1SD 2.2	N = 1.3SD 2.5	N = 70Mean 5.6SD 3.6	N = 67Mean 5.6SD 3.6	N = 2.9SD 4.1	N = 46Mean 1.7SD 2.9	N = 2.1SD 3.4
Complete resolution of enthesitisMASES = 0, n/N (%)	0	74/141(52.5)	75(50.7)	66/104(63.5)	90(60.8)	0	41/74(55.4)	42(53.8)	38/58(65.5)	51(65.4)	0	33/67(49.3)	33(47.1)	28/46(60.9)	39(55.7)
Heel enthesitis complete resolution, n/N(%)	0	32/49(65.3)	32(61.5)	26/35(74.3)	37(71.2)	0	13/23(56.5)	13(52)	12/17(70.6)	17(68)	0	19/26(73.1)	19(70.4)	14/18(77.8)	20(74.1)

Abbreviations: axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; nr-axSpA, non-radiographic axial SpA; OC, observed cases; LOCF, last observation carried forward.

MRI outcomes

MRIs of the sacroiliac (SI) joints and spine were performed at baseline and week 12, 48 and 96.29 For lesions on MRI in the SI joints, the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring method33 was used and for lesions in the spine the Berlin modification of Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) was used.34 Only patients with MRI evidence of inflammation at baseline were analyzed for MRI remission. CZP treatment of patients with axSpA significantly reduced MRI inflammation in the SI joints and spine over 12 weeks.29 Improvements were seen and maintained through week 96 for AS and nr-axSpA patients treated with CZP.29

Nonradiographic axial spondyloarthritis

RAPID-axSpA is the only trial including patients with both r-axSpA and nr-axSpA with either positive C-reactive protein (CRP) or MRI (with stratified randomization for the presence of radiographic sacroiliitis),35 and as mentioned earlier, overlapping results were observed between the two groups for most of the outcomes measured (Table 1). The improvement in disability (Bath Ankylosing Spondylitis Functional Index) was greater for patients with nr-axSpA.35 The effect of etanercept, ADA and golimumab in patients with nr-axSpA was tested in three separate trials.36–38 For all three drugs, responses were not statistically significant and smaller in patients with normal CRP and MRI at baseline.35 In patients who had a positive MRI or an increased CRP (ADA and golimumab) and in patients who had both (etanercept), the effect sizes were far greater and statistically significant.35

In summary, for patients with nr-axSpA, there is good evidence for the efficacy of CZP, etanercept, ADA and golimumab, but their use should be restricted to patients with abnormal CRP and/or MRI.

Safety

The safety profile of these TNFi has been shown in different clinical trials performed in patients with psoriatic and rheumatoid arthritis.39–41

The initial RAPID axSpA trial reported that the adverse events (AEs) were mild to moderate in both CZP and placebo groups. During the 24 weeks of the study, any AE occurred in 62.6% of the placebo group and 76% of the CZP group. Serious AEs occurred in 4.7% and 3.6% of patients in the first group and second group, respectively, and serious infections occurred in 0% and 1.8% of patients in the first group and second group, respectively.28 In the placebo group any AE, serious AEs and serious infections occurred in 74.8%, 6.5% and 0%, respectively.28 No deaths, malignancies or tuberculosis events were observed, and no new safety signals for CZP in AS were observed compared to other indications for CZP.28

Sieper et al described the effects of 315 AS patients in the RAPID ax-SPA trial over 96 weeks. AEs occurred in 279 (88.6%) patients (total exposure period 486/patient years). Most of these side effects were mild (74.9%) or moderate (59.4%).32

They reported serious AEs in 41 patients (13.0%), which were predominantly infections and infestations (3.8%); one case of active tuberculosis was identified. Over the 96-week trial period, there were no fatalities, malignancies or drug-induced demyelinating disease. In total, 215 of the 315 patients were tested for anti-CZP antibodies at week 96, and 9 patients tested positive for the antibodies. They did not investigate the efficacy of CZP in patients who developed anti-CZP antibodies because of the small cohort of patients with positive antibodies.32

A boxed warning on the increased risk of serious infection and latent tuberculosis is included in the US prescribing information.42 In the European Union (EU), CZP is contraindicated in active tuberculosis or other severe infections such as sepsis or opportunistic infections and moderate to severe heart failure (NYHA classes III/IV).43

Although there are no data on long-term safety of CZP in AS, data from treatment of other diseases are useful. Loftus et al collected data from five placebo-controlled trials, nine open-label studies and one dose regimen study with Crohn’s disease and found an IR for serious AEs of 31.35/100 patient-years, very similar to that of placebo (24.33/100 patient-years).44 IRs of serious infections or malignancies did not increase with long-term treatment (6.47/100 patient-years and 0.80/100 patient-years, respectively, in the all-studies group). In a comparable way, IRs of psoriasis or psoriasiform dermatitis did not increase with long-term treatment (0.93/100 patient-years and 0.09/100 patient-years, respectively, in the all-studies group).44

Drug survival is a surrogate of efficacy and safety in observational studies. Recently, results from a two-center cohort of AS patients treated with TNFi (ADA: n= 332, etanercept: n = 205, IFX: n = 51, golimumab: n = 40, and CZP: n = 23) in the United Kingdom have been published.45 Median drug survival duration for first TNFi was 10.2 years, which was superior to second TNFi (5.5 years) (P < 0.05). No drug-specific (P = 0.45) differences were observed for TNFi survival, although follow-up for patients with CZP was shorter.45

All data show that CZP safety profile is very similar to the other TNFi that have been in the market for longer time.

Pregnancy

Drugs used to treat women at fertile age, commonly affected with rheumatic diseases, may alter fertility and increase the risk of miscarriages and congenital abnormalities. On the other side, disease activity could be an independent risk factor for adverse pregnancy outcomes.46–48

Concerns related to the safety of biologics during pregnancy existed until few years ago when data from many studies suggested that pregnant women with inflammatory bowel disease or inflammatory arthritis receiving TNF inhibitors was not associated with adverse pregnancy outcomes or any increase in teratogenicity.49–53

CZP differs from other TNF blockers in that it has no Fc region and is not actively transported through the placenta, and as expected, concentrations in the fetus would be lower.54

In a study performed in 2013, authors measured the serum and cord concentrations of drugs in the mother, infant and cord blood.55 They included 31 pregnant women with inflammatory bowel disease receiving IFX (n=11), ADA (n=10) and CZP (n=10). Drug concentrations in infants at birth and cord were compared with those of the mother. IFX and ADA concentrations were higher in infants at birth and their cords than in their mothers. The median level of IFX and ADA in the cord was 160% and 153% higher than that of the mother, respectively. By contrast, the median level of CZP in the cord was 3.9% higher than that of the mother. They detected IFX and ADA in the infants for as long as 6 months, while CZP in the infant plasma and cord was undetectable. No congenital malformations or adverse pregnancy outcomes were reported.24,55

An analysis of 253 pregnancies with known outcomes from a total of 625 pregnancies from UCB Pharma global safety database was published.56 Only one-third of pregnancies continued the treatment through second or third trimester, while most of women were exposed during the first trimester. Most of the women had Crohn’s disease. In total, 75.5% pregnancies resulted in live births. Ten percent of women had elective terminations, and spontaneous miscarriages were reported in 14% of patients.56 Three congenital malformations were reported after maternal exposure, which is comparable to that of the general population.56

The 2016 “EULAR recommendations for use of antirheumatic drugs during pregnancy and lactation” recommended discontinuing monoclonal antibodies IFX, ADA and golimumab around gestational week 20. Etanercept (a fusion protein) may be continued until week 30–32, and CZP has minimal transplacental passage for use throughout pregnancy but needs confirmation from prospective studies.51

Administration and doses

In the United States, CZP has been approved by FDA only for the treatment of adult patients with active AS.42

In the EU, subcutaneous CZP has been approved for the treatment of patients with severe active AS who have had an inadequate response to or are intolerant to NSAIDs and adults with severe active axSpA without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI who have had an inadequate response to or are intolerant to NSAIDs.43

The recommended doses and administration schedules are 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at weeks 2 and 4, followed by 200 mg every other week or 400 mg every 4 weeks.

The purpose of indicating LD is to achieve high concentrations of the drug during early stages of treatment, which accelerates drug response and reduces the production of drug antibodies.24

Place in therapy

TNFis are recommended in all international and local guidelines after NSAID failure in AS and nr-axSpA.57,58 CZP, a new TNFi, is placed at that same level, although some concerns due to less long-term and real-life date might be raised. CZP demonstrated efficacy not only in axial involvement but also in peripheral arthritis and enthesitis and hence should be considered in patients with more than one involvement. Because of its advantages related to low cross-placental and breast milk transfer, CZP may be considered as the TNFi of choice in female patients considering pregnancy and of course in pregnant patients. As always, risks and benefits of therapy should be discussed with the patient taking into account neonatal risks and the risk of disease flare. Also, the course of a pregnancy with a very active disease might have far more consequences to neonatal development. In general, it is not recommended to switch to CZP if a pregnant patient is doing well on other TNFi. Having other options for the treatment of these patients, is there any advantage to use CZP? Some CZP features, apart from placental and breast milk transfer, that make CZP in some way different to other TNFi might be considered at the time of offering the patient a new treatment: a fortnightly or monthly subcutaneous drug regime due to a long half-life; quick and long-lasting efficacy and low generation of anti-TNFi (anti-ADA) antibodies after a loading dose; and proven good distribution into inflamed tissues due to PEGylation. On the other hand, up to now, in spite of these differences, CZP safety profile looks similar to other TNFi.

Conclusion

CZP, the newest original TNFi, has shown very good efficacy and has sustained on the long term in several manifestations of axSpA, including peripheral disease, enthesitis and PROs.

CZP is a new TNFi with a novel composition that is gaining experience around the world and performing according to expectations.